Hypercapnia and Suppression of Anti-viral Host Defense
高碳酸血症和抗病毒宿主防御的抑制
基本信息
- 批准号:9336504
- 负责人:
- 金额:$ 39.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-17 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute respiratory failureAntiviral AgentsAutophagocytosisBCL2 geneBacterial InfectionsBindingBloodCarbon DioxideCellsCessation of lifeChIP-seqChronic Obstructive Airway DiseaseChronic lung diseaseClinicalCommunitiesCystic FibrosisDefectDrosophila genusExposure toFutureGene ExpressionGenesGeneticGenetic TranscriptionHealthHomeoboxHost DefenseHumanHypercapniaImmuneImmune systemImmunosuppressionIn VitroIndividualInfectionInfluenzaInfluenza A virusInterferon Type IInterferon-alphaInterferon-betaInterferonsInvestigationLungLung diseasesMammalsMediatingMediator of activation proteinMolecularMusMyelogenousNF-kappa BOrthologous GeneOutcomePathologyPathway interactionsPatientsPhagocytosisPlayPneumoniaPredispositionRNA interference screenReportingResearchRiskRisk FactorsRoleSmall Interfering RNASystemTestingTissuesViralVirus DiseasesVirus ReplicationWorkZFHX3 geneZinc Fingersadverse outcomeantimicrobial peptidebaseclinically relevantgenome-wideimmune functionin vivoinfluenzavirusinhibition of autophagykillingsknock-downlung injurymacrophagemortalitymouse modelmutantnovelpreventresearch studytranscription factor
项目摘要
DESCRIPTION (provided by applicant): Hypercapnia the elevation of PCO2 in blood and tissue, commonly occurs in advanced COPD and in acute respiratory failure. Patients with COPD frequently develop bacterial and viral lung infections, including influenza, and hypercapnia is a risk factor for mortality in such individuals. We have shown that hypercapnia suppresses transcription of multiple NF-κB-regulated innate immune genes required for host defense and inhibits phagocytosis and autophagy-mediated bacterial killing by macrophages (MØs). Moreover, we found that hypercapnia increases mortality due to bacterial infections in both mice and Drosophila. These findings strongly suggest that hypercapnia is not simply a marker of advanced lung disease, but that it plays a causal role in poor clinical outcomes by suppressing immune function and increasing susceptibility to infection. The similarity of hypercapnia's effects in Drosophila and mammalian systems suggested that elevated CO2 inhibits innate immune gene expression by conserved pathway(s). Thus, we conducted a genome-wide RNAi screen in Drosophila and identified the zinc finger homeobox transcription factor, zfh2, as a candidate mediator of CO2's immunosuppressive effects. Notably, mutant Drosophila deficient in zfh2 were protected against the CO2-induced increase in mortality from bacterial infection. Next, we found that ZFHX3, a mammalian zfh2 ortholog, is expressed in MØs; that ZFHX3 binds in a CO2-sensitive manner to multiple hypercapnia-regulated MØ genes; and that siRNA knockdown of ZFHX3 blocked hypercapnic immune gene suppression. In preliminary experiments for the current application, we observed that hypercapnia inhibited LPS- and influenza A virus (IAV)-induced expression of type I interferon (IFN) pathway antiviral genes in human and mouse MØs. Notably, ZFHX3 bound IFN regulatory factors (IRFs) and NF-κB genes, and this binding was CO2-sensitive, suggesting that ZFHX3 mediates hypercapnia's effect on antiviral gene expression by blocking IRF- and NF-κB- activated transcription of IFN-α and IFN-β. We also found that hypercapnia suppressed IAV-induced autophagy, another antiviral pathway, and that this followed hypercapnia-induced increases in expression of the negative autophagy regulators, Bcl-2 and Bcl-xL, and activation of Akt. Finally, of critical importance, exposure to elevated CO2 enhanced IAV replication in MØs and other cells and increased the mortality of IAV infection in mice. The proposed studies will test the hypotheses that hypercapnia inhibits expression of IFN pathway antiviral genes via CO2-dependent changes in transcription mediated by ZFHX3; that hypercapnia inhibits IAV-induced autophagy via increased expression of Bcl-2 and Bcl-xL and activation of Akt; and that myeloid ZFHX3 deficiency or blocking hypercapnic inhibition of autophagy will decrease IAV-associated lung injury and mortality in mice. This investigation will define novel mechanisms by which elevated levels of CO2 suppress antiviral host defense, a previously-unrecognized adverse consequence of hypercapnia, and will lay the basis for future studies aimed at preventing hypercapnia-induced immunosuppression in patients with advanced lung disease.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER H SPORN其他文献
PETER H SPORN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER H SPORN', 18)}}的其他基金
Hypercapnia and Suppression of Antiviral Host Defense
高碳酸血症和抗病毒宿主防御的抑制
- 批准号:
10486540 - 财政年份:2022
- 资助金额:
$ 39.13万 - 项目类别:
Hypercapnia and Suppression of Anti-viral Host Defense
高碳酸血症和抗病毒宿主防御的抑制
- 批准号:
9755485 - 财政年份:2017
- 资助金额:
$ 39.13万 - 项目类别:
OXIDANT-INDUCED MACROPHAGE ARACHIDONIC ACID METABOLISM
氧化剂诱导的巨噬细胞花生四烯酸代谢
- 批准号:
3082792 - 财政年份:1991
- 资助金额:
$ 39.13万 - 项目类别:
OXIDANT-INDUCED MACROPHAGE ARACHIDONIC ACID METABOLISM
氧化剂诱导的巨噬细胞花生四烯酸代谢
- 批准号:
3082791 - 财政年份:1990
- 资助金额:
$ 39.13万 - 项目类别:
OXIDANT-INDUCED MACROPHAGE ARACHIDONIC ACID METABOLISM
氧化剂诱导的巨噬细胞花生四烯酸代谢
- 批准号:
3082788 - 财政年份:1990
- 资助金额:
$ 39.13万 - 项目类别:
OXIDANT-INDUCED MACROPHAGE ARACHIDONIC ACID METABOLISM
氧化剂诱导的巨噬细胞花生四烯酸代谢
- 批准号:
3082790 - 财政年份:1990
- 资助金额:
$ 39.13万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 39.13万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 39.13万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 39.13万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 39.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 39.13万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 39.13万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 39.13万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 39.13万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 39.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 39.13万 - 项目类别: